ORG Wealth Partners’s Janux Therapeutics JANX Stock Holding History

ORG Wealth Partners’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$224	Buy	+13	New	+$218	﹤0.01%	2322

Other funds holding JANX

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $2.08B AUM 157.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

ORG Wealth Partners's JANX Position: Q3 2026 in Review

ORG Wealth Partners opened a new position in Janux Therapeutics (JANX) in Q3 2026: 13 shares worth $224. The stake represents ﹤0.01% of the portfolio and ranks #2322 among its holdings.

117 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

ORG Wealth Partners held 13 shares of Janux Therapeutics worth $224 as of Q3 2026.
Janux Therapeutics was a new ORG Wealth Partners position in Q3 2026.
Janux Therapeutics made up ﹤0.01% of ORG Wealth Partners's portfolio in Q3 2026, its #2322 holding.
117 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on ORG Wealth Partners's 13F filing for Q3 2026, filed 3 Nov 2026.